MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

Dysregulation of the mesenchymal epithelial transition (MET) pathway contributes to poor clinical outcomes in patients with non-small cell lung cancer (NSCLC). Numerous clinical trials are currently investigating several therapies based on modulation of the MET pathway.

Objectives

This study aimed to systematically evaluate the activity and safety of MET inhibitors in patients with NSCLC.

Methods

We searched PubMed, Embase, and the Cochrane Library from inception to June 02, 2022. The objective response rate (ORR) and disease control rate (DCR) were extracted as the main outcomes and pooled using the weighted mean proportion with fixed- or random-effects models in cases of significant heterogeneity (I ²>50%). Safety analysis was performed

SUBMITTER: Xu L 

PROVIDER: S-EPMC9646943 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature